View Older Stories

Nov 26, 2025 05:06PM Humacyte terminates stock sale agreement with Jefferies

Nov 13, 2025 09:26AM Humacyte (HUMA) PT Lowered to $11 at Benchmark

Nov 12, 2025 07:07AM Humacyte, Inc. (HUMA) Tops Q3 EPS by 5c

Oct 6, 2025 08:04AM Humacyte reports long-term results for combat injury treatment in Ukraine

Sep 29, 2025 08:01AM Humacyte receives U.S. patent for bioengineered esophagus technology

Sep 18, 2025 07:03AM Humacyte publishes CTEV coronary bypass data, plans human trials

Sep 15, 2025 07:01AM Humacyte publishes study results on Symvess for vascular complications

Sep 12, 2025 05:06PM Humacyte (HUMA) files $350M mixed shelf

Aug 27, 2025 12:59AM Barclays Starts Humacyte (HUMA) at Overweight

Aug 12, 2025 09:47AM Humacyte (HUMA) PT Lowered to $3.50 at TD Cowen

Aug 12, 2025 09:44AM Benchmark Reiterates Buy Rating on Humacyte (HUMA)

Aug 12, 2025 06:42AM Humacyte (HUMA) PT Lowered to $3 at H.C. Wainwright

Aug 11, 2025 09:41AM Humacyte (HUMA) PT Lowered to $7 at BTIG

Aug 11, 2025 07:05AM Humacyte, Inc. (HUMA) Misses Q2 EPS by 8c

Jul 8, 2025 08:10AM Humacyte (HUMA) gains Defense Logistics Agency approval for Symvess access

May 14, 2025 09:49AM Humacyte (HUMA) PT Lowered to $14 at Benchmark

May 13, 2025 07:33AM Humacyte, Inc. (HUMA) Tops Q1 EPS by 48c

Apr 3, 2025 09:50AM TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'

Mar 31, 2025 08:26AM Benchmark Reiterates Buy Rating on Humacyte (HUMA)

Mar 28, 2025 07:41AM Humacyte, Inc. (HUMA) Tops Q4 EPS by 9c

Mar 27, 2025 06:00PM Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess

Mar 26, 2025 03:41PM Humacyte (HUMA) PT Lowered to $5 at TD Cowen

Mar 25, 2025 08:39PM Humacyte (HUMA) Announces Pricing of Public Offering of Common Stock

Mar 25, 2025 04:01PM Humacyte (HUMA) Announces Proposed Public Offering of Common Stock

Mar 10, 2025 11:40AM Humacyte (HUMA) PT Lowered to $7.50 at TD Cowen

Mar 10, 2025 08:02AM Humacyte (HUMA) Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 7, 2025 09:29AM Benchmark Reiterates Buy Rating on Humacyte (HUMA)

Feb 27, 2025 08:02AM Humacyte (HUMA) Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 26, 2025 08:02AM Humacyte (HUMA) Announces Commercial Launch of Symvess for Extremity Vascular Trauma

Jan 28, 2025 08:07AM Humacyte (HUMA) and Pluristyx Announce Gene Editing Partnership

Jan 21, 2025 08:05AM Humacyte (HUMA) Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 16, 2025 05:42PM DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 16, 2025 04:41PM HUMA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HU

Jan 15, 2025 04:37PM HUMA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 17 Deadline in Securities Class Action - H

Jan 13, 2025 09:12PM HUMA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 13, 2025 06:53PM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 12, 2025 09:11PM HUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 12, 2025 08:52AM DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 11, 2025 03:52PM HUMA DEADLINE: ROSEN, A HIGHLY REGARDED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 10, 2025 03:52PM HUMA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 9, 2025 02:10PM HUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 7, 2025 04:30PM HUMA DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 6, 2025 05:51PM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 6, 2025 04:24PM ROSEN, A RANKED AND LEADING FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 5, 2025 12:12PM DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 4, 2025 09:13PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Jan 1, 2025 05:33PM ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Dec 31, 2024 12:06PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Dec 28, 2024 07:30PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA

Dec 28, 2024 09:19AM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

View Older Stories